Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
9,957
Total Claims
$8.1M
Drug Cost
1,135
Beneficiaries
$7,122
Cost/Patient
Risk Score Breakdown 24/100
Score components are additive. Read full methodology
Peer Comparison vs. 5,101 Rheumatology providers
+326%
Opioid rate vs peers
17.3% vs 4.1% avg
+18%
Cost per patient vs peers
$7,122 vs $6,039 avg
+80%
Brand preference vs peers
13.6% vs 7.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Opioid rate is 326% above Rheumatology peers. This is a significant deviation that may reflect a specialized patient population or concerning prescribing patterns.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
17.3%
Opioid Rate
1,721
Opioid Claims
$65K
Opioid Cost
5.8%
Long-Acting Rate
Brand vs Generic
Brand: 1,354 claims · $7.7M
Generic: 8,577 claims · $339K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Adalimumab | 288 | $2.7M |
| Etanercept | 140 | $1.1M |
| Certolizumab Pegol | 62 | $451K |
| Immun Glob G(Igg)/Gly/Iga 0-50 | 19 | $425K |
| Secukinumab | 38 | $292K |
| Upadacitinib | 38 | $247K |
| Belimumab | 38 | $230K |
| Golimumab | 30 | $228K |
| Sarilumab | 51 | $211K |
| Tofacitinib Citrate | 36 | $205K |
| Abatacept | 28 | $164K |
| Etanercept | 20 | $157K |
| Apremilast | 38 | $153K |
| Abatacept | 21 | $116K |
| Hydroxychloroquine Sulfate | 1,329 | $99K |
Prescribing Profile
Patient Profile
71
Avg Age
76%
Female
1.45
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About